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Adenosine is implicated in the modulation of cardiovascular responses either at the peripheral or
at central level in experimental animals. However, there are no dedicated reviews on the involve-
ment of adenosine in mediating the hypotensive response of centrally administered clonidine in
general and speciﬁcally in aortically barodenervated rats (ABD). The conscious ABD rat model
exhibits surgically induced baroreﬂex dysfunction and exaggerated hypotensive response, com-
pared with conscious sham-operated (SO) rats. The current review focuses on, the role of aden-
osine receptors in blood pressure (BP) regulation and their possible crosstalk with other receptors
e.g. imidazoline (I1) and alpha (a2A) adrenergic receptor (AR). The former receptor is a molec-
ular target for clonidine, whose hypotensive effect is enhanced approx. 3-fold in conscious ABD
rats. We also discussed how the balance between the brain stem adenosine A1 and A2A receptors
is regulated by baroreceptors and how such balance inﬂuences the centrally mediated hypoten-
sive responses. The use of the ABD rat model yielded insight into the downstream signaling cas-
cades following clonidine-evoked hypotension in a surgical model of baroreﬂex dysfunction.
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The current review focuses on, the role of adenosine receptors in
BP regulation and their possible crosstalk with other receptors
e.g. imidazoline (I1) and a2A AR in a rat model of surgically-
induced baroreﬂex dysfunction, the ABD rat. Furthermore,
the current review delineates the role of the downstream adenos-
inergic-signaling pathway in mediating the centrally evoked
hypotension elicited by clonidine and clonidine such as drugs.
The review covers data generated in our laboratory and reported
pertinent studies over the past 10 years, which covered the fol-
lowing: (i) imidazoline I1-receptor and centrally mediated hypo-
tension; (ii) clonidine and aortic barodenervation; (iii) clonidine
and SHR rats; (iv) clonidine effects in the RVLM; (v) clonidine
effects in the NTS; (vi) central adenosine receptor signaling;
and (vii) central MAPK-NOS signaling.
The nucleus of the solitary tract (NTS)
The NTS mediates inhibitory actions of baroreceptors on sym-
pathetic discharge and is considered the main site of termina-
tion of the baroreceptor afferent ﬁbers via both the aortic
depressor nerve and the glossopharyngeal (IX) from the caro-
tid sinus [1–3]. Notably, lesions to the NTS abolish the barore-
ﬂex responses [3]. Several reports have shown important roles
for activation of NTS glutamate [1,3] as well as adenosine
receptors in BP regulation [1,2,4–7].
Rostral and caudal ventrolateral medulla
A large body of evidence supports the view that the RVLM is
the major brain stem area that controls sympathetic drive by
projecting directly to the spinal cord [1,8–10]. Neuronal activa-
tion in the RVLM causes an increase in arterial pressure med-
iated by an increase in peripheral resistance, cardiac output,
and secretion of catecholamines [1]. Electrical and chemical
stimulation of the RVLM produces immediate and marked
increases in arterial pressure. The direct connection with the
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in the RVLM neuronal activity dramatically inﬂuences sympa-
thetic neuronal discharge (SND) and arterial pressure (AP)
[1,8–10]. The RVLM-spinal neuronal connection plays at least
two important roles in sympathetic and cardiovascular con-
trol. First, RVLM-spinal neurons set the tone for AP by pro-
viding a basal SND. This tone generating ability explains why
chemical inhibition or lesioning of the RVLM causes a dra-
matic fall in arterial pressure [1]. Second, a dominant aspect
of the RVLM neurons is the control of the baroreﬂex response.
By serving as a major neuroanatomical target for centrally act-
ing antihypertensive agents including clonidine, moxonidine,
and rilmenidine [3], the RVLM plays a fundamental role in
BP regulation and in the control of BP in treated hyperten-
sives. Similar to the NTS, the RVLM expresses receptors
including the adenosine, a2A adrenergic and imidazoline recep-
tors [11,12]. It is not surprising that the RVLM shares with the
NTS a similar receptor population since it receives inhibitory
projections from the NTS and is involved in mediating barore-
ceptor efferent response via the sympathetic nervous system
[1]. It must also be remembered that the caudal ventrolateral
medulla (CVLM) plays important intermediate role between
the NTS and RVLM, particularly in regulating the baroreﬂex
function [3]. Unlike the anatomically and functionally (sym-
pathoexcitatory) well deﬁned neurons of the RVLM, the
CVLM neurons are more heterogeneous and scattered [3].
However, functional and retrograde studies revealed projec-
tions from the NTS to the CVLM, which sends tonic sympath-
oinhibitory projections to the RVLM [3].The aortic barodenervated (ABD) rat model
Various genetic models of hypertension, knockout mice, pheo-
chromocytoma (PC12) cells and anesthetized animals have
been used extensively to outline the signaling cascades trig-
gered by adenosine, imidazoline (I1) and a2A adrenergic recep-
tor activation [13–26]. However, little is known about the role
of these receptors in BP control or BP responses to centrally
acting drugs in conscious rats. Notably, clonidine-evoked
hypotension is evident in conscious or anesthetized hyperten-
sive rats [27–29], but only occurs in anesthetized normotensive
rats [25,30]. In conscious intact rats, the hypotensive response
elicited by clonidine is virtually absent in marked contrast to
the case in the conscious aortic barodenervated rats.
Following denervation, acute rises in BP, heart rate, and
peripheral resistance are apparent in the ABD rat while cardiac
index and stroke volume were not altered. Forty-eight hours
later, when cardiovascular measurements were conducted in
the absence of anesthesia, the reductions in cardiac index
and stroke volume were paralleled by a return of the BP of
conscious ABD rats to sham-operated levels while the periph-
eral resistance remained signiﬁcantly elevated. Compared to
sham operated rats, clonidine (30 lg/kg, i.v.) elicited greater
decreases in BP in ABD rats via decreases in cardiac index
and stroke volume because peripheral resistance did not
change [31–33]. However, these studies focused on the role
of baroreceptor dysfunction and sympathetic nervous system
over-activity as underlying causes for the enhanced response
to some centrally acting hypotensive drugs [31,34]. Other
reported studies built on these ﬁndings to delineate the central
pathways and cellular mechanisms implicated in this responsein the ABD rat. Speciﬁcally, this review focuses on studies that
elucidated the role of central adenosine receptor signaling in
the conscious ABD rat model and their involvement in cen-
trally mediated hypotension.Adenosine receptors in the CNS
The high afﬁnity A1 and the A2A receptors in the brain are ton-
ically activated by extracellular adenosine, which set the basal
‘‘purinergic’’ tone seen in most systems. This notion is sup-
ported by the ability of caffeine to antagonize the actions of
endogenous adenosine and reversing the tonic inhibition [35].
Four different adenosine receptors have been characterized
pharmacologically, structurally and functionally and are
denoted A1, A2A, A2B and A3 [35–37].Role of central adenosine receptors in blood pressure control
The primary neurons that regulate sympathetic outﬂow
located in the NTS and the RVLM, express adenosine recep-
tors [1,2,12,13,23,38–43]. While activation of the A1 receptor
by adenosine, or by the more selective agonist N6-cyclopentyl-
adenosine, causes a pressor response, adenosine A2A receptor
activation by adenosine, or by the more selective agonist, 2-
p-(2-carboxyethyl) phenylethylamino-50-N-ethylcarboxamido-
adenosine (CGS21680), causes a depressor response [2,44–47].Adenosine receptor signal transduction mechanisms
The original delineation of adenosine receptors is based on
their regulation of cyclic adenosine monophosphate (cAMP)
levels. The A1 and A3 receptors mediate a reduction in
cAMP via Gai/o whereas the A2A receptor mediates elevation
in cAMP via Gas [20,48–50]. Notably, the A2A and A2B are
also linked to Gaq and the activation of PKC [20,21,51].
Contrary to previous views where receptor activation leads
to a sequential downstream signaling paradigm, recent evi-
dence suggests that single receptor activation may converge
on a multitude of downstream signaling cascades. In line with
this concept, adenosine receptor activation results in the phos-
phorylation of the mitogen-activated protein kinase (MAPK
p44/42), also known as pERK1/2, through either PLC-DAG
or the PKA pathways [20]. The well-conserved and diverse
MAPK family, which covers three main groups, the extracellu-
lar signal-regulated protein kinases (ERK), the stress-activated
protein kinases (SAPK; p38) and the c-Jun N-terminal kinases
(JNK), is involved in cell cycle progression, proliferation and
differentiation in all organisms including mammals.
Adenosine receptor signaling may enhance or inhibit prolifer-
ation of a variety of cell types depending on the adenosine
receptor (or combination of adenosine receptor) subtypes
and the tissue type. All adenosine receptors activate at least
one MAPK. For example, the Gas-coupled adenosine A2A
receptor activation enhances ERK1/2 phosphorylation as sum-
marized in Fig. 1.
Reported studies including ours implicated central adeno-
sine receptors in BP modulation in at least some forms of
hypertension. Microinjection of adenosine into the nucleus
tractus solitarius (NTS) elicited enhanced depressor and
reduced pressor responses in the SHR compared to its
Fig. 1 ERK1/2 activation following stimulation of A2A receptor
based on ﬁndings obtained from receptor transfected CHO cells,
PC12 cells and human endothelial cells. Abbreviations are: cyclic
adenosine monophosphate (cAMP); protein kinase A (PKA); Raf-
1 is a serine/threonine-speciﬁc kinase (Raf-1); G protein (specif-
ically a small GTPase) (RAS). Adopted with modiﬁcation [20].
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alteration in the central adenosine receptor signaling as a result
of hypertension or due to baroreceptor dysfunction, which is a
hallmark of hypertension. As detailed below, similar altera-
tions occur in adenosine receptor function in the aortic barode-
nervated (ABD) rat, which shares with the SHR a reduced
baroreceptor function [31,52,53]. These ﬁndings suggest a func-
tional link between baroreceptor function/dysfunction and cen-
tral adenosine receptor signaling in the ABD rat model.
Imidazoline receptors and centrally acting antihypertensive
agents
In clinical or experimental hypertension, central sympatholyt-
ics such as clonidine, rilmenidine and moxonidine reduce sym-
pathetic tone and renin release, which ultimately reduces
peripheral resistance and BP [54]. These centrally acting med-
ications lower BP primarily by targeting the RVLM neurons in
the brain stem to cause inhibition of the activity of bulbospinal
sympathoexcitatory presympathetic neurons [11,55].
Additionally, clonidine-like drugs can reduce norepinephrine
released by activating peripheral presynaptic a2A adrenergic
receptors on axon terminals of postganglionic sympathetic
neurons [55].
There has been an ongoing debate regarding the primary
target in the medulla oblongata that is mediating the central
sympathoinhibitory action of central sympatholytic drugs.
Originally, for clonidine-like drugs, it was thought that the pri-
mary target was the a2A AR. However, in 1984, Bousquet et al.
[56] proposed that activation of the imidazoline I1 receptor in
the RVLM accounts for the central sympathoinhibition caused
by clonidine. The fact that direct administration of a-adrener-
gic receptor agonists with a phenylethylamine structure into
the RVLM did not mimic the effects of agonists with imidaz-
oline structure supported the imidazoline receptor hypothesis
[56,57]. Further, blockade of the a2A AR in the RVLM didnot reverse the hypotension elicited by local imidazoline I1
receptor activation [58,59]. On the contrary, the hypotensive
action of clonidine analogues was attenuated by microinjec-
tions of idazoxan or efaroxan, antagonists with imidazoline
structures, into RVLM [11,60–62]. Several imidazoline prefer-
ring compounds such as rilmenidine and moxonidine possess
preferential binding to the I1 receptor over the a2A AR com-
pared to clonidine, which is a mixed I1/a2A AR agonist
[11,55,63–65]. However, functional studies in a2A AR knock-
outs have shown that despite rilmenidine and moxonidine
I1R selectivity, the a2A AR is an important mediator of their
hypotensive action [58,66–69]. Other studies have suggested
synergy between the a2A AR and the I1 receptor signaling
pathways [14,15]. The imidazoline binding site is a separate
entity based on binding and functional studies that demon-
strated the ability of selective I1 receptor agonists (LNP509)
to lower BP when microinjected into the brain stem of
D79N mice [14,68,70]. D79N mice constitute a functional
a2A AR knockout model, which has been useful in elucidating
the role of a2A AR in several functions including hypotension
and sedation [71].
Although it is not known whether the I1 and a2A AR are
operating in parallel or in series, there is evidence that the I1
receptor downstream signaling is distinct from that of the a2A
AR receptor. Several reports have shown that in PC12 cells,
which exhibit neuronal phenotype when differentiated, activa-
tion of the I1 receptor involves the phosphatidylcholine-selective
phospholipase-C (PC-PLC) and PKC (b11 and f isoforms) path-
way and the increased formation of the second messenger diac-
ylglycerol (DAG). As a consequence of the activation of PKC,
ERK1/2 phosphorylation is increased [19,72–74]. These cellular
events contribute to I1 (rilmenidine) mediated hypotension
because similar to I1 receptor blockade (efaroxan), PC-PLC
(D609), or pERK1/2 (PD98059) inhibition abrogated the hypo-
tensive response and the corresponding cellular events elicited
by the I1 receptor activation [18,19,22,72,74]. Noteworthy,
other neuromodulators in the CNS, including L-glutamate and
adenosine, which also enhance ERK1/2 phosphorylation
[20,75] might be implicated in I1 receptor signaling. In support
of this notion, L-glutamate release increases following clonidine
or rilmenidine administration [17,76–78] and L-glutamate
releases adenosine [79,80] (Fig. 2).Crosstalk between adenosine and imidazoline receptors signaling
underlies clonidine-evoked hypotension in conscious ABD rats
Evidence for the involvement of central adenosine receptors in
clonidine-evoked hypotension is supported by a number of
pharmacological studies. The ﬁnding that systemic administra-
tion of theophylline virtually abolished the hypotensive effect
of clonidine inferred a central interaction of these two drugs
because clonidine lowers BP via a central mechanism of action
[81], and theophylline gains access to the CNS to block central
adenosine receptors [13]. This ﬁnding was consolidated by the
observation that intracisternal, but not systemic, administra-
tion, of the water-soluble adenosine receptor blocker 8-p-sul-
phophenyl-theophylline (8-SPT) attenuated clonidine-evoked
hypotension. The inability of systemic 8-SPT, which blocks
peripheral, but not central, adenosine receptors [13,23] to inﬂu-
ence clonidine-evoked hypotension [82] bolsters the conclusion
that central adenosine receptors are implicated in clonidine-
Fig. 2 Schematic overview of a potential I1 and adenosine
receptors crosstalk. Reference is made to the signaling cascades of
the adenosine A1 and A2A receptor subtypes. Adenosine A2A
receptor activation with the nonselective agonist adenosine or the
more selective agonist CGS21680 leads to enhanced expression of
pERK1/2 via a cAMP-dependent or independent mechanism. I1
activation with its respective agonist, clonidine or rilmenidine,
enhances expression of pERK1/2 via a PC-PLC pathway. pERK1/
2 activates neuronal nitric oxide synthase (NOS) which causes
increased production of NO and decreased sympathetic neuronal
activity.
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SCH58261, a selective A2A receptor blocker [83,84], virtually
abolished the clonidine-evoked hypotension [82]. Together,
these ﬁndings suggest the dependence of clonidine-evoked
hypotension on central adenosine A2A receptor.
Although Bousquet et al. [85] classiﬁed clonidine as ligand
at the imidazoline-binding site, clonidine is still considered a
mixed I1/a2A AR agonist [27,85]. Therefore, it was difﬁcult
to ascertain the type of receptor, I1 or a2A, whose activation
triggers central adenosine signaling. Findings from our labora-
tory indicate that the central hypotensive response elicited by
selective activation of the central I1 (rilmenidine) or a2A (a-
MNE) receptor was attenuated by central adenosine receptor
blockade [82]. It is imperative to note that although a-MNE
is considered a ‘‘pure’’ a2A receptor agonist [65], the selective
I1 agonist rilmenidine also exhibits a2A agonist activity
[27,55]. Together, these ﬁndings raise the interesting possibility
that a2A receptor activation might also trigger central adeno-
sine receptor signaling [82]. However, an alternative explana-
tion is that I1 activation by rilmenidine might depend on a
downstream a2A AR activation as proposed by Head [66].
Collectively, these ﬁndings suggest that the adenosinergic sys-
tem plays a critical role in mediating centrally mediated hypo-
tension. However, the use of non-selective adenosine receptor
blockers (theophylline or 8-SPT) in these earlier studies pre-
cluded ascertaining the adenosine receptor subtype implicatedin the mediation of clonidine-evoked hypotension. Building on
the A2A receptor as a viable candidate because its activation
within the brain stem leads to hypotension [4], data from our
laboratory conﬁrmed A2A involvement because the selective
A2A receptor antagonist SCH58261 virtually abolished cloni-
dine-evoked hypotension in conscious ABD rats [82].
Reciprocal roles for central A1 and A2A in blood pressure
regulation
A number of studies including ours demonstrated functionally
opposite roles for central A2A and A1 adenosine receptors in
BP regulation because they mediate depressor, and pressor
responses, respectively [2,4,6,47]. These ﬁndings lead to the
postulate that concomitant activation of the adenosine A1
receptor might counterbalance (mask) the adenosine A2A-
dependent hypotensive action of clonidine, as discussed above.
Our laboratory showed that upregulations of a2A AR and
I1 receptors were paralleled with similar A2A receptor upregu-
lation in the same brain stem areas of the ABD rat model [29].
The latter conﬁrms and extends earlier ﬁndings, which demon-
strated the upregulation of a2 and I1 receptors in the same ani-
mal model [32,86]. It might be argued that aortic
barodenervation caused nonspeciﬁc upregulation of adenosine
A2A as well as the a2A AR and I1 receptors because they fol-
lowed the same pattern in the investigated brain stem nuclei.
However, such parallel upregulation might be physiologically
relevant because: (i) the A2A receptor, the a2A and the I1 recep-
tors in the NTS and RVLM are spatially associated, (ii) all
three receptors mediate hypotension [2,55,65,86], and (iii) their
shared signaling pathways make it highly likely that these
receptors physiologically interact [18–20]. These ﬁndings are
consistent with a key role for central adenosine A2A in cloni-
dine evoked hypotension in conscious ABD rats [82].
Overexpressed adenosine A2A receptor in brain stem is
functionally relevant
Immunohistochemical evidence demonstrated approximately
twofold increase in the number of A2A receptors in the NTS
and RVLM of ABD, compared to SO, rats [87]. These ﬁndings
were functionally relevant because the selective adenosine A2A
agonist CGS21680 elicited signiﬁcantly greater dose-dependent
hypotensive responses in the ABD, compared to SO, rats [29].
Notably, particularly in the NTS and RVLM, the A2A receptor
activation produces sympathoinhibition and hypotension
[2,12,47], which are shared by clonidine and similar drugs
[18,31,82,86]. Together, these ﬁndings establish a link between
the anatomical and functional upregulation of brain stem aden-
osine A2A receptor in the ABD rat [31,32]. Equally important,
these ﬁndings might explain, at least partly, the enhanced hypo-
tensive response elicited by clonidine in ABD rats [31,82] and its
dependence on central adenosine A2A receptor signaling [82].
ERK1/2-NOS activation underlies centrally mediated
hypotension
As discussed earlier, ERK1/2 phosphorylation constitutes
important signaling event in clonidine-evoked hypotension.
Noteworthy, pERK1/2 involvement in I1 receptor-evoked
Fig. 3 Conceptual overview of the major ﬁndings discussed in
this review. Upregulation of A2A (large circle) and the molecular
targets for clonidine (I1/a2A, large circles) are more evident in
ABD rats (right hand side) compared to sham-operated, SO, rats
(left hand side, small circles). Note the downregulation of A1
(small circle) in ABD compared to SO rats (large circle) in the
NTS and RVLM. Direct (CGS21680) or indirect (clonidine)
central A2A activation enhances pERK1/2 expression, which
subsequently phosphorylates NOS (increased NO) and ultimately
reduces BP. Blockade of central A2A receptor (SCH58261) or
inhibition of NOS (L-NAME) abrogated clonidine-evoked hypo-
tension, but only the former abrogated clonidine-evoked elevation
in pERK1/2 expression. Intracisternal A1 receptor blockade
(DPCPX) (large circle) unravels clonidine-evoked hypotension
and enhances pERK1/2 expression in conscious normotensive
rats. Central A1 receptor is downregulated in the NTS and RVLM
(small circle) in ABD compared to SO rats (large circle), which is
paralleled by an attenuated pressor response to adenosine A1
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expression in the RVLM is enhanced in association with cen-
trally mediated hypotension elicited by rilmenidine, but not
by a-methylnorepinephrine [18] and (ii) the ERK1/2 phosphor-
ylation inhibitor PD98059 signiﬁcantly attenuated rilmenidine-
evoked hypotension [18]. By the same token, the exaggerated
hypotensive response elicited by central A2A receptor activa-
tion with i.c. CGS21680 in ABD rats might involve enhance-
ment of ERK1/2 phosphorylation [87]. Further, central A2A
receptor blockade, which virtually abolished clonidine-evoked
hypotension [82], abrogated the associated increase in brain
stem ERK1/2 phosphorylation (pERK1/2). The latter ﬁndings
suggest the involvement of the A2A receptor signaling in the
centrally evoked hypotensive response elicited by clonidine
and other I1R agonists. It was reasoned that NOS activation
(phosphorylation) is triggered by pERK1/2 based on an estab-
lished signaling pathway in cultured cells [88,89], and because
NOS-derived NO causes sympathoinhibition and hypotension
[90]. This intriguing possibility is supported: (i) by pharmaco-
logic inhibition of ERK1/2 phosphorylation attenuated cloni-
dine-evoked hypotension and ERK1/2 and NOS
phosphorylation in the RVLM and (ii) while L-NAME abro-
gated clonidine-evoked hypotension without affecting the
enhanced ERK1/2 phosphorylation in the RVLM [87]. These
ﬁndings are consistent with a role for pERK1/2 as an upstream
activator of NOS [87,91] and bolster the conclusion that
pERK1/2 plays a pivotal role in centrally-mediated hypoten-
sion via downstream NOS activation (enhanced NO produc-
tion). Further, these reported ﬁndings rule out the possibility
that ERK1/2 phosphorylation was consequence of clonidine-
evoked hypotension in the ABD model system. Together, these
ﬁndings delineate the molecular events in the brain stem trig-
gered by central adenosine A2A receptor activation and suggest
a biological relevance for the pERK1/2-NOS pathway in-vivo.
By contrast, we showed that the latter signaling pathway con-
tributes to the central CB1R-mediated pressor response [92] via
GABA dependent mechanisms. Future studies are needed to
address this controversy because the adenosine A2 receptors
are expressed on GABAergic neurons of the medulla oblon-
gata of the developing rat brain.
Why clonidine fails to lower BP in conscious normotensive rats?
Many reported ﬁndings, including ours showed that clonidine
does not lower BP [31,34,93,94] or inﬂuence ERK1/2 phos-
phorylation in the NTS and RVLM [87] in conscious normo-
tensive rats. By contrast, as discussed above, clonidine
enhances pERK1/2 expression and lowers BP in conscious
ABD rats via adenosine A2A receptor dependent mechanisms.
These ﬁndings set forth the postulate that concomitant adeno-
sine A1 receptor activation serves a negative (counterbalanc-
ing) role against adenosine A2A receptor signaling triggered
by clonidine in conscious normotensive rats. In support of this
hypothesis are the ﬁndings that clonidine signiﬁcantly reduced
BP and increased brain stem pERK1/2 expression following
central adenosine A1 receptor blockade (DPCPX) in conscious
normotensive rats [29]. Interestingly, these molecular and BP
responses were similar to those elicited by clonidine in ABD
rats [31,82]. Collectively, these ﬁndings support a dampening
role for central adenosine A1 receptor against clonidine-
evoked hypotension and advance our knowledge in this areaof research because central adenosine A1 receptor blockade
(i) unmasked clonidine-evoked hypotension and the enhanced
phosphorylation of brain stem pERK1/2 in conscious normo-
tensive rats and (ii) had no effect on the neurochemical
(pERK1/2) or the hypotensive response elicited by clonidine
in ABD rats. These ﬁndings are consistent with opposite roles
for central A1 (pressor) and A2A (depressor) receptor activa-
tion [2,6] and further support a pivotal role for brain stem
pERK1/2 in the hypotensive action of clonidine and similar
drugs [18].
Finally, it is imperative to comment on the differential
expression of the adenosine A1 receptor in the NTS and
RVLM of SO and ABD rats. We demonstrated an inverse rela-
tionship between the level of adenosine A1 receptor expression
and the BP response to clonidine [29] in marked contrast to a
direct relationship between A2A receptor expression in the
same brain nuclei and the hypotensive effect of clonidine in
ABD rats [29,87]. It is likely, therefore, that the balance
between the A1 and the A2A adenosine receptor populationsreceptor activation (CPA) in ABD, compared to SO, rats.
Adenosine and central hypotension 337in the brain stem determines the magnitude of the BP response
elicited by clonidine and perhaps other centrally acting drugs.
Tipping the balance toward adenosine A2A dominance might
explain the enhanced clonidine-evoked hypotension in con-
scious ABD rats [82,87] and SHRs [13]. It is also important
to discuss the role of the NTS adenosine A1 receptor in BP reg-
ulation and how it might be impacted by anesthesia. In gen-
eral, anesthesia dampens the NTS A1-mediated pressor
response because Machado and de Paula [95] showed that
intra-NTS adenosine produced pressor response via activation
of the local A1 receptor in conscious rats. These ﬁndings
explain, at least partly, why systemic or intracisternal clonidine
lowers BP in anesthetized, but not in conscious rats. Consistent
with this knowledge, as discussed above, suppression of aden-
osine A1 (and concomitant upregulation of A2) receptors in the
brain stem occurs in the ABD rat and clonidine lowers BP in
this animal model in the conscious state [82]. Nonetheless,
the NTS neurons are heterogeneous because our reported stud-
ies showed that under the same experimental condition (anes-
thetized rats), microinjection of adenosine into the rostral and
caudal NTS produced pressor and depressor responses, respec-
tively [13]. Whether the adenosine A1/A2 ratios are different in
these two subareas of the NTS remains to be elucidated.
Conclusions
The reviewed pharmacological and molecular ﬁndings support
a differential role of adenosine A2A and A1 receptors in medi-
ating and opposing clonidine-evoked hypotension, respec-
tively. This review also provides a brief account on the role
of pERK1/2-NOS-NO activation in brain stem nuclei as a
molecular mechanism for the centrally mediated hypotension
elicited by direct and indirect activation of the central A2A
receptor by CGS21680 and clonidine, respectively. Further,
the reviewed ﬁndings support the conclusion that pERK1/2
is a mediator and not a result of the hypotension elicited by
direct or indirect A2A receptor activation. This is the ﬁrst
review that discussed the novel mechanism that central A1
receptor signaling masks clonidine-evoked hypotension in con-
scious normotensive rats (summarized in Fig. 3). Since cloni-
dine is clinically used for the management of hypertension,
possible drug interactions with the adenosine agonists and
antagonists that cross the blood brain barrier might have clin-
ical implications.
Conﬂict of interest
The authors have declared no conﬂict of interest.
Compliance with Ethics Requirements
This article does not contain any studies with human or animal
subjects.Acknowledgment
This study was supported in part by National Institutes of
Health Grant 2R01 AA07839.References
[1] Sun MK. Central neural organization and control of
sympathetic nervous system in mammals. Prog Neurobiol
1995;47(3):157–233.
[2] Scislo TJ, O’Leary DS. Purinergic mechanisms of the nucleus of
the solitary tract and neural cardiovascular control. Neurol Res
2005;27(2):182–94.
[3] Colombari E, Sato MA, Cravo SL, Bergamaschi CT, Campos Jr
RR, Lopes OU. Role of the medulla oblongata in hypertension.
Hypertension 2001;38(3 Pt 2):549–54.
[4] Scislo TJ, Kitchen AM, Augustyniak RA, O’Leary DS.
Differential patterns of sympathetic responses to selective
stimulation of nucleus tractus solitarius purinergic receptor
subtypes. Clin Exp Pharmacol Physiol 2001;28(1–2):120–4.
[5] Scislo TJ, O’Leary D S. Vasopressin V1 receptors contribute to
hemodynamic and sympathoinhibitory responses evoked by
stimulation of adenosine A2a receptors in the NTS. Am J
Physiol Heart Circ Physiol 2005.
[6] Scislo TJ, O’Leary DS. Mechanisms mediating regional
sympathoactivatory responses to stimulation of NTS A(1)
adenosine receptors. Am J Physiol Heart Circ Physiol
2002;283(4):H1588–99.
[7] Scislo TJ, Tan N, O’Leary DS. Differential role of nitric oxide in
regional sympathetic responses to stimulation of NTS A2a
adenosine receptors. Am J Physiol Heart Circ Physiol
2005;288(2):H638–49.
[8] Guyenet PG. The sympathetic control of blood pressure. Nat
Rev Neurosci 2006;7(5):335–46.
[9] Kumagai H, Oshima N, Matsuura T, Iigaya K, Imai M,
Onimaru H, et al. Importance of rostral ventrolateral medulla
neurons in determining efferent sympathetic nerve activity and
blood pressure. Hypertens Res 2012;35(2):132–41.
[10] Braga VA, Colombari E, Jovita MG. Angiotensin II-derived
reactive oxygen species underpinning the processing of the
cardiovascular reﬂexes in the medulla oblongata. Neurosci Bull
2011;27(4):269–74.
[11] Head GA, Mayorov DN. Imidazoline receptors, novel agents
and therapeutic potential. Cardiovasc Hematol Agents Med
Chem 2006;4(1):17–32.
[12] Thomas T, St Lambert JH, Dashwood MR, Spyer KM.
Localization and action of adenosine A2a receptors in regions
of the brainstem important in cardiovascular control.
Neuroscience 2000;95(2):513–8.
[13] Abdel-Rahman AA, Tao S. Differential alteration of neuronal
and cardiovascular responses to adenosine microinjected into
the nucleus tractus solitarius of spontaneously hypertensive rats.
Hypertension 1996;27(4):939–48.
[14] Bruban V, Estato V, Schann S, Ehrhardt JD, Monassier L,
Renard P, et al. Evidence for synergy between alpha(2)-
adrenergic and nonadrenergic mechanisms in central blood
pressure regulation. Circulation 2002;105(9):1116–21.
[15] Bruban V, Feldman J, Greney H, Dontenwill M, Schann S,
Jarry C, et al. Respective contributions of alpha-adrenergic and
non-adrenergic mechanisms in the hypotensive effect of
imidazoline-like drugs. Br J Pharmacol 2001;133(2):261–6.
[16] Arslan G, Kull B, Fredholm BB. Signaling via A2A adenosine
receptor in four PC12 cell clones. Naunyn Schmiedebergs Arch
Pharmacol 1999;359(1):28–32.
[17] Zhang J, Abdel-Rahman AA. The hypotensive action of
rilmenidine is dependent on functional N-methyl-D-aspartate
receptor in the rostral ventrolateral medulla of conscious
spontaneously hypertensive rats. J Pharmacol Exp Ther
2002;303(1):204–10.
[18] Zhang J, Abdel-Rahman AA. Mitogen-activated protein kinase
phosphorylation in the rostral ventrolateral medulla plays a key
338 N.N. Nassar and A.A. Abdel-Rahmanrole in imidazoline (i1)-receptor-mediated hypotension. J
Pharmacol Exp Ther 2005;314(3):945–52.
[19] Zhang J, El-Mas MM, Abdel-Rahman AA. Imidazoline I(1)
receptor-induced activation of phosphatidylcholine-speciﬁc
phospholipase C elicits mitogen-activated protein kinase
phosphorylation in PC12 cells. Eur J Pharmacol 2001;415(2–
3):117–25.
[20] Schulte G, Fredholm BB. Signalling from adenosine receptors to
mitogen-activated protein kinases. Cell Signal
2003;15(9):813–27.
[21] Schulte G, Fredholm BB. The G(s)-coupled adenosine A(2B)
receptor recruits divergent pathways to regulate ERK1/2 and
p38. Exp Cell Res 2003;290(1):168–76.
[22] Separovic D, Kester M, Haxhiu MA, Ernsberger P. Activation
of phosphatidylcholine-selective phospholipase C by I1-
imidazoline receptors in PC12 cells and rostral ventrolateral
medulla. Brain Res 1997;749(2):335–9.
[23] Tao S, Abdel-Rahman AA. Neuronal and cardiovascular
responses to adenosine microinjection into the nucleus tractus
solitarius. Brain Res Bull 1993;32(4):407–17.
[24] Yamamoto J. Cardiovascular response to acute stress in
spontaneously hypertensive rats. Hypertension 1987;10(5):550.
[25] Yang J, Wang WZ, Shen FM, Su DF. Cardiovascular effects of
agmatine within the rostral ventrolateral medulla are similar to
those of clonidine in anesthetized rats. Exp Brain Res
2005;160(4):467–72.
[26] Barac YD, Bar-Am O, Liani E, Amit T, Frolov L, Ovcharenko
E, et al. I1 imidazoline receptor: novel potential cytoprotective
target of TVP1022, the S-enantiomer of rasagiline. PLoS One
2012;7(11):e47890.
[27] Estato V, Araujo CV, Bousquet P, Tibirica E. Effects of
centrally acting antihypertensive drugs on the microcirculation
of spontaneously hypertensive rats. Braz J Med Biol Res
2004;37(10):1541–9.
[28] Jastrzebski Z, Czyzewska-Szafran H, Gozlinska B,
Remiszewska M, Mazurek AP. Clonidine hypotension in
spontaneously hypertensive rats (SHR) depends on the
functional state of GABAergic and glutamatergic systems.
Neurosci Lett 1995;184(2):94–6.
[29] Nassar N, Abdel-Rahman AA. Brainstem adenosine A1
receptor signaling masks phosphorylated extracellular signal-
regulated kinase 1/2-dependent hypotensive action of clonidine
in conscious normotensive rats. J Pharmacol Exp Ther
2009;328(1):83–9.
[30] El-Mas MM, Tao S, Carroll RG, Abdel-Rahman AA. Ethanol-
clonidine hemodynamic interaction in normotensive rats is
modiﬁed by anesthesia. Alcohol 1994;11(4):307–14.
[31] Abdel-Rahman AA. Aortic baroreceptors exert a tonically
active restraining inﬂuence on centrally mediated depressor
responses. J Cardiovasc Pharmacol 1992;19(2):233–45.
[32] El-Mas MM, Abdel-Rahman AA. Aortic barodenervation up-
regulates alpha2-adrenoceptors in the nucleus tractus solitarius
and rostral ventrolateral medulla: an autoradiographic study.
Neuroscience 1997;79(2):581–90.
[33] Medvedev OS, Kunduzova OR, Murashev AN, Medvedeva
NA. Inﬂuence of sino-aortic barodenervation on the
cardiovascular effects of imidazoline-like drugs. J Auton Nerv
Syst 1998;72(2–3):205–9.
[34] Bonham AC, Trapani AJ, Portis LR, Brody MJ. Studies on the
mechanism of the central antihypertensive effect of guanabenz
and clonidine. J Hypertens Suppl 1984;2(3):S543–6.
[35] Dunwiddie TV, Masino SA. The role and regulation of
adenosine in the central nervous system. Annu Rev Neurosci
2001;24:31–55.
[36] Fredholm BB, AP IJ, Jacobson KA, Klotz KN, Linden J.
International union of pharmacology. XXV. Nomenclature and
classiﬁcation of adenosine receptors. Pharmacol Rev 2001;53(4):
527–52.[37] Poulsen SA, Quinn RJ. Adenosine receptors: new opportunities
for future drugs. Bioorg Med Chem 1998;6(6):619–41.
[38] Chen S, He RR. Effect of intracarotid injection of adenosine on
the activity of RVLM neurons in barodenervated rats. Sheng Li
Xue Bao 1998;50(6):629–35.
[39] Thomas T, Spyer KM. The role of adenosine receptors in the
rostral ventrolateral medulla in the cardiovascular response to
defence area stimulation in the rat. Exp Physiol 1996;81(1):
67–77.
[40] Scislo TJ, O’Leary DS. Dkifferential control of renal vs. adrenal
sympathetic nerve activity by NTS A2a and P2x purinoceptors.
Am J Physiol 1998;275(6 Pt 2):H2130-9.
[41] Scislo TJ, O’Leary DS. Activation of A2a adenosine receptors in
the nucleus tractus solitarius inhibits renal but not lumbar
sympathetic nerve activity. J Auton Nerv Syst 1998;68(3):
145–52.
[42] Spyer KM, Lambert JH, Thomas T. Central nervous system
control of cardiovascular function: neural mechanisms and
novel modulators. Clin Exp Pharmacol Physiol 1997;24(9–
10):743–7.
[43] St Lambert JH, Dashwood MR, Spyer KM. Role of brainstem
adenosine A1 receptors in the cardiovascular response to
hypothalamic defence area stimulation in the anaesthetized rat.
Br J Pharmacol 1996;117(2):277–82.
[44] Barraco RA, el-Ridi MR, Ergene E, Phillis JW. Adenosine
receptor subtypes in the brainstem mediate distinct
cardiovascular response patterns. Brain Res Bull 1991;26(1):
59–84.
[45] Barraco RA, Janusz CJ, Polasek PM, Parizon M, Roberts
PA. Cardiovascular effects of microinjection of adenosine into
the nucleus tractus solitarius. Brain Res Bull
1988;20(1):129–32.
[46] Barraco RA, Phillis JW. Subtypes of adenosine receptors in the
brainstem mediate opposite blood pressure responses.
Neuropharmacology 1991;30(4):403–7.
[47] Scislo TJ, O’Leary DS. Adenosine receptors located in the NTS
contribute to renal sympathoinhibition during hypotensive
phase of severe hemorrhage in anesthetized rats. Am J Physiol
Heart Circ Physiol 2006.
[48] Freissmuth M, Selzer E, Schutz W. Interactions of puriﬁed
bovine brain A1-adenosine receptors with G-proteins.
Reciprocal modulation of agonist and antagonist binding.
Biochem J 1991;275(Pt 3):651–6.
[49] Akbar M, Okajima F, Tomura H, Shimegi S, Kondo Y. A single
species of A1 adenosine receptor expressed in Chinese hamster
ovary cells not only inhibits cAMP accumulation but also
stimulates phospholipase C and arachidonate release. Mol
Pharmacol 1994;45(5):1036–42.
[50] Jockers R, Linder ME, Hohenegger M, Nanoff C, Bertin B,
Strosberg AD, et al. Species difference in the G protein
selectivity of the human and bovine A1-adenosine receptor. J
Biol Chem 1994;269(51):32077–84.
[51] Fresco P, Diniz C, Queiroz G, Goncalves J. Release inhibitory
receptors activation favours the A2A-adenosine receptor-
mediated facilitation of noradrenaline release in isolated rat
tail artery. Br J Pharmacol 2002;136(2):230–6.
[52] El-Mas MM, Abdel-Rahman AA. Role of aortic baroreceptors
in ethanol-induced impairment of baroreﬂex control of heart
rate in conscious rats. J Pharmacol Exp Ther 1992;262(1):
157–65.
[53] Takeda K, Hayashi J, Itoh H, Hirata M, Nakata T, Oguro M,
et al. Transection of aortic depressor nerve fails to raise blood
pressure in spontaneously hypertensive rats. Cardiovasc Res
1989;23(7):573–6.
[54] Dubar M, Pillion G. I1 agents: a new approach to the treatment
of hypertension. Ann NY Acad Sci 1995;763:642–58.
[55] Szabo B, Bock C, Nordheim U, Niederhoffer N. Mechanism of
the sympathoinhibition produced by the clonidine-like drugs
Adenosine and central hypotension 339rilmenidine and moxonidine. Ann NY Acad Sci 1999;881:
253–64.
[56] Bousquet P, Feldman J, Schwartz J. Central cardiovascular
effects of alpha adrenergic drugs: differences between
catecholamines and imidazolines. J Pharmacol Exp Ther
1984;230(1):232–6.
[57] Ernsberger P, Giuliano R, Willette RN, Reis DJ. Role of
imidazole receptors in the vasodepressor response to clonidine
analogs in the rostral ventrolateral medulla. J Pharmacol Exp
Ther 1990;253(1):408–18.
[58] Reis DJ, Piletz JE. The imidazoline receptor in control of blood
pressure by clonidine and allied drugs. Am J Physiol 1997;273(5
Pt 2):R1569–71.
[59] Bousquet P. Identiﬁcation and characterization of I1
imidazoline receptors: their role in blood pressure regulation.
Am J Hypertens 2000;13(6 Pt 2):84S–8S.
[60] Chan CK, Head GA. Relative importance of central imidazoline
receptors for the antihypertensive effects of moxonidine and
rilmenidine. J Hypertens 1996;14(7):855–64.
[61] Haxhiu MA, Dreshaj I, Schafer SG, Ernsberger P. Selective
antihypertensive action of moxonidine is mediated mainly by I1-
imidazoline receptors in the rostral ventrolateral medulla. J
Cardiovasc Pharmacol 1994;24(Suppl 1):S1–8.
[62] Feldman J, Tibirica E, Bricca G, Dontenwill M, Belcourt A,
Bousquet P. Evidence for the involvement of imidazoline
receptors in the central hypotensive effect of rilmenidine in the
rabbit. Br J Pharmacol 1990;100(3):600–4.
[63] Ernsberger P, Haxhiu MA. The I1-imidazoline-binding site is a
functional receptor mediating vasodepression via the ventral
medulla. Am J Physiol 1997;273(5 Pt 2):R1572–9.
[64] Tolentino-Silva FP, Haxhiu MA, Waldbaum S, Dreshaj IA,
Ernsberger P. Alpha(2)-adrenergic receptors are not required for
central anti-hypertensive action of moxonidine in mice. Brain
Res 2000;862(1–2):26–35.
[65] Szabo B. Imidazoline antihypertensive drugs: a critical review on
their mechanism of action. Pharmacol Ther 2002;93(1):1–35.
[66] Head GA. Central imidazoline- and alpha 2-receptors involved
in the cardiovascular actions of centrally acting antihypertensive
agents. Ann NY Acad Sci 1999;881:279–86.
[67] Bousquet P, Bruban V, Schann S, Greney H, Ehrhardt JD,
Dontenwill M, et al. Participation of imidazoline receptors
and alpha(2-)-adrenoceptors in the central hypotensive
effects of imidazoline-like drugs. Ann NY Acad Sci 1999;
881:272–8.
[68] Guyenet PG. Is the hypotensive effect of clonidine and related
drugs due to imidazoline binding sites? Am J Physiol 1997;273(5
Pt 2):R1580–4.
[69] Tan CM, Wilson MH, MacMillan LB, Kobilka BK, Limbird
LE. Heterozygous alpha 2A-adrenergic receptor mice unveil
unique therapeutic beneﬁts of partial agonists. Proc Natl Acad
Sci USA 2002;99(19):12471–6.
[70] Ernsberger P, Friedman JE, Koletsky RJ. The I1-imidazoline
receptor: from binding site to therapeutic target in
cardiovascular disease. J Hypertens Suppl 1997;15(1):S9–S23.
[71] Kable JW, Murrin LC, Bylund DB. In vivo gene modiﬁcation
elucidates subtype-speciﬁc functions of alpha(2)-adrenergic
receptors. J Pharmacol Exp Ther 2000;293(1):1–7.
[72] Ernsberger P. The I1-imidazoline receptor and its cellular
signaling pathways. Ann NY Acad Sci 1999;881:35–53.
[73] Separovic D, Kester M, Ernsberger P. Coupling of I1-
imidazoline receptors to diacylglyceride accumulation in PC12
rat pheochromocytoma cells. Mol Pharmacol 1996;49(4):668–75.
[74] Edwards L, Ernsberger P. The I(1)-imidazoline receptor in PC12
pheochromocytoma cells reverses NGF-induced ERK activation
and induces MKP-2 phosphatase. Brain Res 2003;980(1):71–9.
[75] Choe ES, Chung KT, Mao L, Wang JQ. Amphetamine increases
phosphorylation of extracellular signal-regulated kinase andtranscription factors in the rat striatum via group I
metabotropic glutamate receptors. Neuropsychopharmacology
2002;27(4):565–75.
[76] Tingley 3rd FD, Arneric SP. Evidence for clonidine
presynaptically modulating amino acid release in the rostral
ventral medulla: role in hypertension. Brain Res 1990;537(1–
2):175–81.
[77] Wang WZ, YuanWJ, Su DF. Blockade of N-methyl-D-aspartate
receptors within the rostral ventrolateral medulla antagonizes
clonidine-induced cardiovascular effects. Auton Neurosci
2003;109(1–2):21–8.
[78] Wang WZ, Yuan WJ, Tang CS, Su DF. Electrophysiological
evidences for the contribution of NMDA receptors to the
inhibition of clonidine on the RVLM presympathetic neurons.
Brain Res 2004;1023(1):163–6.
[79] Iliff JJ, D’Ambrosio R, Ngai AC, Winn HR. Adenosine
receptors mediate glutamate-evoked arteriolar dilation in the
rat cerebral cortex. Am J Physiol Heart Circ Physiol
2003;284(5):H1631–7.
[80] Paes-de-Carvalho R, Dias BV, Martins RA, Pereira MR,
Portugal CC, Lanfredi C. Activation of glutamate receptors
promotes a calcium-dependent and transporter-mediated release
of purines in cultured avian retinal cells: possible involvement of
calcium/calmodulin-dependent protein kinase II. Neurochem
Int 2005;46(6):441–51.
[81] van Zwieten PA. Renewed interest in centrally acting
antihypertensive drugs. Cardiovasc J S Afr 2000;11(4):225–9.
[82] Nassar N, Abdel-Rahman AA. Central adenosine signaling
plays a key role in centrally mediated hypotension in conscious
aortic barodenervated rats. J Pharmacol Exp Ther
2006;318(1):255–61.
[83] Beukers MW, den Dulk H, van Tilburg EW, Brouwer J,
Ijzerman AP. Why are A(2B) receptors low-afﬁnity adenosine
receptors? Mutation of Asn273 to Tyr increases afﬁnity of
human A(2B) receptor for 2-(1-Hexynyl)adenosine. Mol
Pharmacol 2000;58(6):1349–56.
[84] Ongini E, Dionisotti S, Gessi S, Irenius E, Fredholm BB.
Comparison of CGS 15943, ZM 241385 and SCH 58261 as
antagonists at human adenosine receptors. Naunyn
Schmiedebergs Arch Pharmacol 1999;359(1):7–10.
[85] Bousquet P, Greney H, Bruban V, Schann S, Ehrhardt JD,
Monassier L, et al. I(1) imidazoline receptors involved in
cardiovascular regulation: where are we and where are we
going? Ann NY Acad Sci 2003;1009:228–33.
[86] El-Mas MM, Abdel-Rahman AA. Upregulation of imidazoline
receptors in the medulla oblongata accounts for the enhanced
hypotensive effect of clonidine in aortic barodenervated rats.
Brain Res 1995;691(1–2):195–204.
[87] Nassar N, Abdel-Rahman AA. Brainstem phosphorylated
extracellular signal-regulated kinase 1/2-nitric-oxide synthase
signaling mediates the adenosine A2A-dependent hypotensive
action of clonidine in conscious aortic barodenervated rats. J
Pharmacol Exp Ther 2008;324(1):79–85.
[88] Lee SA, Park JK, Kang EK, Bae HR, Bae KW, Park HT.
Calmodulin-dependent activation of p38 and p42/44 mitogen-
activated protein kinases contributes to c-fos expression by
calcium in PC12 cells: modulation by nitric oxide. Brain Res
Mol Brain Res 2000;75(1):16–24.
[89] Wyatt AW, Steinert JR, Wheeler-Jones CP, Morgan AJ, Sugden
D, Pearson JD, et al. Early activation of the p42/p44MAPK
pathway mediates adenosine-induced nitric oxide production in
human endothelial cells: a novel calcium-insensitive mechanism.
Faseb J 2002;16(12):1584–94.
[90] Chan SH, Wang LL, Wang SH, Chan JY. Differential
cardiovascular responses to blockade of nNOS or iNOS in
rostral ventrolateral medulla of the rat. Br J Pharmacol
2001;133(4):606–14.
340 N.N. Nassar and A.A. Abdel-Rahman[91] Shen SC, Wu MS, Lin HY, Yang LY, Chen YH, Chen YC.
Reactive oxygen species-dependent nitric oxide production in
reciprocal interactions of glioma and microglial cells. J Cell
Physiol 2014.
[92] Ibrahim BM, Abdel-Rahman AA. Enhancement of rostral
ventrolateral medulla neuronal nitric-oxide synthase-nitric-
oxide signaling mediates the central cannabinoid receptor 1-
evoked pressor response in conscious rats. J Pharmacol Exp
Ther 2012;341(3):579–86.
[93] El-Mas MM, Carroll RG, Abdel-Rahman AA. Blood
pressure normalization in carotid barodenervated rats: roleof cardiac output. Can J Physiol Pharmacol 1993;71(10–
11):783–90.
[94] El-Mas MM, Carroll RG, Abdel-Rahman AA. Centrally
mediated reduction in cardiac output elicits the enhanced
hypotensive effect of clonidine in conscious aortic
barodenervated rats. J Cardiovasc Pharmacol 1994;24(2):
184–93.
[95] de Paula PM, Machado BH. Antagonism of adenosine A(1)
receptors in the NTS does not affect the chemoreﬂex in awake
rats. Am J Physiol Regul Integr Comp Physiol 2001;281(6):
R2072–8.
